United States

Alchemia Ltd (ACL.AX)

ACL.AX on Australia Stock Exchange

Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Alchemia announces sale of Fondaparinux IP to Dr. Reddy's Laboratories
Thursday, 24 Sep 2015 06:26pm EDT 

Alchemia Ltd:Sale of Fondaparinux Ip.Under binding terms of sale, Alchemia will receive US$17.5 million in cash from Dr. Reddy's.Received a payment of US$1.15 million for its share of net profit from US- only sales of fondaparinux for the quarter ending 30 June 2015.Entered into binding term sheet for sale of the intellectual property rights to fondaparinux sodium to Dr. Reddy's Laboratories.  Full Article

Alchemia Limited updates on conditional sale of Oncology subsidiary
Sunday, 2 Aug 2015 08:00pm EDT 

Alchemia Limited:In discussions with panther biotechnology to extend initial 30-day exclusivity period to sell subsidiary, Alchemia Oncology Pty Ltd.In addition to filing prospectus, completion of sale subject to panther successfully raising funds and listing shares on NASDAQ by 28 October 2015.  Full Article

Alchemia announces appointment of chairman
Thursday, 9 Jul 2015 08:48pm EDT 

Alchemia Limited:Announces the appointment of Ken Poutakidis as interim chairman of the board of directors.Says Nathan Drona has been appointed as chairman of the audit, compliance and risk committee.  Full Article

Alchemia Limited executes binding term sheet for the sale of Alchemia Oncology Pty Ltd
Tuesday, 30 Jun 2015 06:00pm EDT 

Alchemia Limited:Says that it has executed a binding term sheet for the sale of its 100 pct. owned subsidiary, Alchemia Oncology Pty Ltd, with US biotechnology company, Panther Biotechnology Inc.  Full Article

More From Around the Web